Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Richtig, E; Langmann, G; Schlemmer, G; Müllner, K; Papaefthymiou, G; Bergthaler, P; Smolle, J.
Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma
OPHTHALMOLOGE. 2006; 103(6): 506-511. Doi: 10.1007/s00347-006-1350-7
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Richtig Erika
Co-Autor*innen der Med Uni Graz
Langmann Gerald
Müllner Katharina
Papaefthymiou Georgios
Schlemmer Gregor
Smolle Josef

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

PURPOSE: In this manuscript, the safety and efficacy of adjuvant interferon alfa 2b treatment of uveal melanoma is described.PATIENTS AND METHODS: A total of 39 patients (23 male and 16 female, mean age 56.5 years, range 35-78 years) with uveal melanoma were treated with interferon alfa 2b, 3 million units three times a week subcutaneously for 1 year after therapy of the primary tumor. In all patients age, gender, primary melanoma data, therapeutic interventions, treatment side effects and outcome were documented.RESULTS: Of the 39 patients, 31 (80%) finished the treatment as scheduled after 1 year. In 18 patients (46%) the initial dose had to be reduced due to leucopenia, thrombopenia, cardiac symptoms, elevated of liver function or vertigo (WHO grade I-III). In eight patients, therapy had to be withdrawn because of serious side effects (five patients) and the appearance of metastases (three patients). Neither a univariate approach nor a multivariate approach could show a protective effect of interferon treatment on survival.CONCLUSIONS: Adjuvant treatment of uveal melanoma with interferon alfa should be abandoned until the question of dose and administration for cutaneous melanoma is solved.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Antineoplastic Agents - administration and dosage
Chemotherapy, Adjuvant - administration and dosage
Female - administration and dosage
Humans - administration and dosage
Interferon Alfa-2b - administration and dosage
Male - administration and dosage
Melanoma - drug therapy
Middle Aged - drug therapy
Risk Assessment - methods
Risk Factors - methods
Treatment Outcome - methods
Uveal Neoplasms - drug therapy

Find related publications in this database (Keywords)
uveal melanoma
adjuvant treatment
interferon alfa
© Med Uni Graz Impressum